EODData

MEMBERSHIP REGISTER LOG IN

FRA, 04K: Knight Therapeutics Inc

11 Nov 2025
LAST:

3.680

CHANGE:
 0.04		OPEN:
3.680		HIGH:
3.680		ASK:
0.000		VOLUME:
100
CHG(%):
1.08		PREV:
3.720		LOW:
3.680		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
11 Nov 253.6803.6803.6803.680100
10 Nov 253.7203.7203.7203.720100
07 Nov 253.6603.6603.6603.660100
06 Nov 253.5603.5603.5603.560100
05 Nov 253.5603.5603.5603.560100
04 Nov 253.6003.6003.6003.600100
03 Nov 253.6003.6003.6003.600100
31 Oct 253.5203.5203.5203.520100
30 Oct 253.5403.5403.5403.540100
29 Oct 253.5803.5803.5803.580100

COMPANY PROFILE

Name:Knight Therapeutics Inc
About:Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, the company finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
Sector:Healthcare
Address:3400 de Maisonneuve Blvd. W., Montreal, QC, Canada, H3Z 3B8
Website:https://www.knighttx.com
ISIN:CA4990531069

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:65.33 
Forward P/E:80.65 
PEG Ratio:0.12 
Price to Sales:0.95 
Price to Book:0.47 
Profit Margin:0.00 
Operating Margin:-0.03 
Return on Assets:-0.01 
Return on Equity:0.00 
Revenue:237.58M 
EBITDA:29.97M 
Shares:99.65M 
Market Cap:366.72M 

TECHNICAL INDICATORS

MA5:3.641.2%
MA10:3.602.2%
MA20:3.582.9%
MA50:3.690.3%
MA100:3.762.1%
MA200:3.751.8%
STO9:80.00 
STO14:80.00 
RSI14:58.33
WPR14:-20.00 
MTM14:0.12
ROC14:0.03 
ATR:0.03 
Week High:3.721.1%
Week Low:3.563.4%
Month High:3.721.1%
Month Low:3.461.8%
Year High:4.0510.0%
Year Low:3.408.4%
Volatility:8.97